ALSO NOTED: Thailand may bust cancer patents; Watson scores marketing rights from Depomed;

> Thailand is mulling patent-breaking compulsory licenses for three cancer drugs, including one from Novartis, one from Sanofi-Aventis, and one from Genentech. Report

> Depomed and Watson Pharmaceuticals expanded a marketing agreement to give Watson the right to promote the UTI drug ProQuin in the OB/GYN market. Report

> Cubist Pharmaceuticals got Health Canada's OK to market its Cubicin intravenous antibiotic for skin infections and certain gram-positive infections. Report

> Indian drug maker Cadila Pharmaceutical got the FDA's nod for its rheumatoid arthritis remedy hydroxychloroquine sulfate. Report

> Lupin will invest $10 million in a new steroid-manufacturing facility in Indore, India. Report

And Finally... Space-traveling microbes get better, stronger, faster--just what we need, right? Yes, say researchers who think subjecting germs to extreme conditions may lead to new therapies for cancer and infectious disease. Report

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.